Mode
Text Size
Log in / Sign up

PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD

PON1 genetic variants rs2057681 and rs854572 modulate PONase activity and dysmetabolic risk in MASLD
Photo by Giovanni Crisalfi / Unsplash
Key Takeaway
Consider PON1 genetic configuration over enzyme activity alone when assessing dysmetabolic risk in MASLD patients.

This observational cohort study enrolled 922 Portuguese individuals from the PREVADIAB2 cohort to investigate the role of PON1 genetic variants in metabolic liver disease. The primary exposure was PON1 genetic variants rs2057681 and rs854572, along with their haplotypes, while the primary outcome was PONase activity. Secondary outcomes included dysglycemia and liver fibrosis risk within the context of metabolic dysfunction-associated steatotic liver disease (MASLD).

Main results indicated that specific combinations of rs854572-rs2057681 haplotypes differentially modulated PONase activity. These genetic configurations conferred either risk or protection against dysglycemia and liver fibrosis, with the direction of effect dependent on the rs2057681 genotype context. Conversely, dysmetabolic phenotypes did not directly correlate with measured PONase activity levels.

Safety and tolerability data were not reported in this genetic association study. Key limitations include the finding that PONase activity alone does not shape disease susceptibility, as associations are described as dependent on genetic configuration rather than enzyme activity. The study setting was Portugal, and no specific follow-up duration was reported. Practice relevance supports using PON1 genetic information to uncover predisposition to dysmetabolic conditions and for risk stratification in metabolic liver disease, noting that causality cannot be inferred from this observational design.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background & AimsMetabolic disorders such as dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), and diabetes are promoted by chronic pro-inflammatory and pro-oxidative states. Paraoxonase 1 (PON1), a liver-derived HDL-associated enzyme, plays an important antioxidant role by hydrolyzing oxidized lipids and protecting against oxidative stress- induced damage. Genetic variation in PON1, particularly in promoter and coding regions, modulates enzyme expression and activity, thereby influencing susceptibility to metabolic and cardiovascular diseases. This study investigated the genetic determinants of serum paraoxonase (PONase) activity and their relationship with dysmetabolic phenotypes. MethodsA genome-wide association study was conducted in 922 Portuguese individuals from the PREVADIAB2 cohort. Genetic variants and haplotypes related to PONase activity were analyzed, and associations with dysglycemia and liver fibrosis were evaluated in individuals aged over 55 years. ResultsWe identified two key PON1 variants as determinants of PONase activity: rs2057681 (in strong linkage disequilibrium with the non-synonymous Q192R variant) and rs854572 (located in the promoter region). Analysis of rs854572-rs2057681 haplotypes revealed that specific combinations differentially modulate PONase activity and confer risk or protection for dysglycemia and liver fibrosis, depending on the rs2057681 genotype context. Notably, although PONase activity was strongly associated with PON1 variants, it did not directly correlate with dysmetabolic phenotypes, suggesting that genetic context and haplotype structure, rather than enzyme activity alone, shape disease susceptibility. ConclusionsThese findings highlight the complex genetic architecture of PON1 and its role in metabolic disease risk, supporting the use of PON1 genetic information to uncover predisposition to dysmetabolic conditions. Our results provide insights into the interplay between PON1 genetics, enzyme function, and dysmetabolism, with implications for risk stratification in metabolic liver disease. Lay SummaryPON1 is a liver-derived gene that encodes an enzyme involved in protection against oxidative stress, a key contributor to metabolic liver disease and diabetes. In this study, we found that specific combinations of PON1 genetic variants are associated with abnormalities in blood glucose regulation and with markers of liver fibrosis. These associations were dependent on genetic configuration rather than enzyme activity alone, suggesting that PON1 genetic information may help identify individuals at higher risk of metabolic liver disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.